ATM ATR DNA damage response
Selected indexed studies
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. (Mol Cell, 2017) [PMID:28622525]
- The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. (Adv Cancer Res, 2010) [PMID:21034966]
- DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. (Signal Transduct Target Ther, 2020) [PMID:32355263]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. (2017) pubmed
- The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. (2010) pubmed
- DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. (2020) pubmed
- DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. (2025) pubmed
- ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. (2007) pubmed
- APE1 is a master regulator of the ATR-/ATM-mediated DNA damage response. (2024) pubmed
- DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition. (2025) pubmed
- Shelterin-Mediated Telomere Protection. (2018) pubmed
- H2AX: A key player in DNA damage response and a promising target for cancer therapy. (2024) pubmed
- State-of-the-art strategies for targeting the DNA damage response in cancer. (2019) pubmed